PRA partners up to accelerate vaccine R&D

PRA Health Sciences has joined forces with a trial site group to focus on vaccine development, hoping to speed up patient recruitment and get more clinical studies rolling.

Chiltern expands in diabetes after a big buyout

CRO Chiltern, in the process of integrating its latest acquisition, is focusing in on endocrinology and metabolism, broadening its expertise with an eye on diabetes R&D.

Patheon rebrands with a $100M IPO in the works

Contract drug developer Patheon is revamping its brand identity on the way to Wall Street, tinkering with its image ahead of a planned $100 million IPO.

U.K. CRO Venn buys up another contractor

Venn Life Sciences is expanding its reach across Europe, buying a small Dutch contractor to bolster its offerings in regulatory affairs.

ShangPharma plots a $60M splash for biologics R&D in China

Chinese contract drug developer ShangPharma is planning to invest $60 million to build a biologics research and manufacturing outpost near its home base in Shanghai.

German CRO cozies up to Bayer at its Berlin R&D hub

German preclinical CRO NMI TT Pharmaservices is building a new branch at Bayer's new hub for biotech startups, hoping to expand the use of its discovery platform.

Covance plots a deeper dive into manufacturing

Covance, now a division of LabCorp, is planning to build a second manufacturing-enabled pharmacy adjacent to one of its clinical research sites, allowing the CRO to churn out doses of investigational drugs for ongoing studies.

BioClinica reaches into regulatory affairs with its latest buy

The acquisitive BioClinica has picked up another service provider, buying a company specializing in safety monitoring and regulatory affairs to build out its offerings in drug development.

Chiltern closes its Theorem buy, doubling its workforce

U.K. CRO Chiltern has wrapped up its acquisition of former U.S. competitor Theorem Clinical Research, expanding its payroll and global reach in the process.

PRA adding 150 jobs amid Pennsylvania expansion push

PRA Health Sciences is building up its presence in Pennsylvania, adding 150 jobs with plans to dial up recruitment over the next two years.

Accelovance inks a nonprofit partnership for melanoma trials

CRO Accelovance is teaming up with a cancer-focused nonprofit to broaden its services in oncology trials, widening its net of expert investigators.

AMRI turns its revenue guidance after a $174M buyout

AMRI is brightening its expectations for 2015 after closing its latest buyout, counting on its manufacturing division to keep revenue rolling.

WuXi brings its genomic heft to Chinese patients with hospital pact

WuXi PharmaTech, making use of its recent $65 million investment in genomics, is teaming up with a Shanghai hospital to expand the scope of precision medicine in its home country.

Evotec upsizes its 2015 projections after a string of partnering deals

German research outfit Evotec is dialing up its full-year revenue expectations thanks to a series of contract wins.

Aragen licenses a protein technology to speed up biologics R&D

CRO Aragen Biosciences signed a deal with Dutch service provider ProteoNic Biotechnology to get its hands on a protein-production technology it believes can improve biologics development.

Rho snags a $120M federal contract with NIH

Private CRO Rho inked its largest-ever federal contract, signing a 7-year deal with the U.S. National Institutes of Health that will pay out about $16.5 million each year.

Evotec teams up with Pfizer for fibrosis R&D

Hybrid R&D outfit Evotec signed a deal with Pfizer to collaborate on tissue fibrosis research, lending its expertise and discovery technology to the pharma giant in exchange for a cut of the benefits.

Recipharm signs on to make LobSor's Parkinson's drug as it negotiates with Novartis

Swedish contract drugmaker Recipharm signed a deal with neighboring LobSor Pharmaceuticals to manufacture the company's new treatment for Parkinson's disease, all the while discussing a partnership with Novartis in the field of eye care.

Icon teams up with IBM to accelerate clinical trial startup

CRO giant Icon is working with IBM in hopes of making clinical trials more efficient, tapping the company's famed Watson technology with an eye on speeding up recruitment and site selection.

Surging dollar blunts Catalent's revenue, but profits soar in fiscal '15

Catalent watched as some unfavorable currency trends sapped its fiscal year revenue growth, but the company closed out its transformational year with a major increase in profits that management said is a sign of things to come.